Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Gains from Sales and Divestitures (2018 - 2025)

Fortress Biotech (FBIO) has 8 years of Gains from Sales and Divestitures data on record, last reported at $737132.0 in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 3109.25% year-over-year to $737132.0; the TTM value through Sep 2025 reached $737132.0, up 3109.25%, while the annual FY2024 figure was $17303.0, 67.75% down from the prior year.
  • Gains from Sales and Divestitures reached $737132.0 in Q3 2025 per FBIO's latest filing, up from $152585.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $882753.0 in Q4 2022 and bottomed at $17206.0 in Q1 2024.
  • Average Gains from Sales and Divestitures over 5 years is $261404.4, with a median of $197917.0 recorded in 2021.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 95.55% in 2024, then soared 3109.25% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $374825.0 in 2021, then skyrocketed by 135.51% to $882753.0 in 2022, then crashed by 93.92% to $53658.0 in 2023, then plummeted by 67.75% to $17303.0 in 2024, then skyrocketed by 4160.14% to $737132.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $737132.0 in Q3 2025, $152585.0 in Q2 2025, and $77124.0 in Q1 2025.